Advertisement
U.S. Markets closed

Chromocell Therapeutics Corporation (CHRO)

NYSE American - Nasdaq Real Time Price. Currency in USD
Visitors trend2W10W9M
0.7299+0.0344 (+4.95%)
At close: 03:59PM EDT
Advertisement
Show:
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
0
0
0
0
199.934
Operating Expense
8,869
6,862
2,318
838.996
1,554
Operating Income
-8,869
-6,862
-2,318
-838.996
-1,354
Net Non Operating Interest Income Expense
-929.752
-518.509
-140.43
-0.253
-1.676
Other Income Expense
-
-
-
243.862
694.959
Pretax Income
-9,795
-7,381
-2,459
-595.387
-660.584
Tax Provision
0
0
0
0
0
Net Income Common Stockholders
-9,795
-7,381
-2,459
-595.387
-660.584
Diluted NI Available to Com Stockholders
-9,795
-7,381
-2,459
-595.387
-660.584
Basic EPS
0.03
-1.28
-0.26
-0.10
-0.07
Diluted EPS
0.03
-1.28
-0.26
-0.10
-0.07
Basic Average Shares
15,564
5,768
9,287
5,768
9,287
Diluted Average Shares
15,564
5,768
9,287
5,768
9,287
Total Operating Income as Reported
-8,869
-6,862
-2,318
-838.996
-1,354
Total Expenses
8,869
6,862
2,318
838.996
1,554
Net Income from Continuing & Discontinued Operation
-9,795
-7,381
-2,459
-595.387
-660.584
Normalized Income
-9,795
-7,381
-2,459
-839.249
-1,356
Interest Expense
929.752
518.509
140.43
0.253
1.676
Net Interest Income
-929.752
-518.509
-140.43
-0.253
-1.676
EBIT
-8,865
-6,862
-2,318
-595.134
-658.908
EBITDA
-8,865
-6,862
-2,318
-595.134
-658.908
Net Income from Continuing Operation Net Minority Interest
-9,795
-7,381
-2,459
-595.387
-660.584
Total Unusual Items Excluding Goodwill
-
-
0
243.862
694.959
Total Unusual Items
-
-
0
243.862
694.959
Normalized EBITDA
-8,865
-6,862
-2,318
-838.996
-1,354
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0